Evidence map›Paper›PMID 31872292›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2020

Depressive symptoms, mental health-related quality of life, and survival among older patients with multiple myeloma.

Ali Alobaidi, Nadia A Nabulsi, Brian Talon, Alemseged A Asfaw, Jifang Zhou, Lisa K Sharp, Karen Sweiss, Pritesh R Patel, Naomi Y Ko, Brian C-H Chiu and 1 more

Abstract read
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Impact of depression on adherence to lenalidomide plus low-dose dexamethasone in patients with relapsed or refractory myeloma.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ali AlobaidiDepartment of Pharmacy Systems, Outcomes and Policy, Center for Pharmacoepidemiology and Pharmacoeconomic Research, University of Illinois at Chicago, 833 S. Wood St. MC 871, Chicago, IL, 60612, USA.
Nadia A NabulsiDepartment of Pharmacy Systems, Outcomes and Policy, Center for Pharmacoepidemiology and Pharmacoeconomic Research, University of Illinois at Chicago, 833 S. Wood St. MC 871, Chicago, IL, 60612, USA.
Brian TalonDepartment of Pharmacy Systems, Outcomes and Policy, Center for Pharmacoepidemiology and Pharmacoeconomic Research, University of Illinois at Chicago, 833 S. Wood St. MC 871, Chicago, IL, 60612, USA.
Alemseged A AsfawDepartment of Pharmacy Systems, Outcomes and Policy, Center for Pharmacoepidemiology and Pharmacoeconomic Research, University of Illinois at Chicago, 833 S. Wood St. MC 871, Chicago, IL, 60612, USA.
Jifang ZhouDepartment of Pharmacy Systems, Outcomes and Policy, Center for Pharmacoepidemiology and Pharmacoeconomic Research, University of Illinois at Chicago, 833 S. Wood St. MC 871, Chicago, IL, 60612, USA.
Lisa K SharpDepartment of Pharmacy Systems, Outcomes and Policy, Center for Pharmacoepidemiology and Pharmacoeconomic Research, University of Illinois at Chicago, 833 S. Wood St. MC 871, Chicago, IL, 60612, USA.
Karen SweissDepartment of Pharmacy Practice, University of Illinois at Chicago, Chicago, IL, USA.
Pritesh R PatelDivision of Hematology and Oncology, Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA.
Naomi Y KoSection of Hematology Oncology, Boston University School of Medicine, Boston, MA, USA.
Brian C-H ChiuDepartment of Public Health Sciences, The University of Chicago, Chicago, IL, USA.
Gregory S CalipDepartment of Pharmacy Systems, Outcomes and Policy, Center for Pharmacoepidemiology and Pharmacoeconomic Research, University of Illinois at Chicago, 833 S. Wood St. MC 871, Chicago, IL, 60612, USA. gcalip@uic.edu.ORCID http://orcid.org/0000-0002-7744-3518

Funding

Institutional Career DevelopmentKL2TR002002 · NCATS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI PHILLIPS, SHANE A · 2016 to 2024
$6.8M
Epigenomic markers of circulating cell-free DNA and treatment outcome in multiple myelomaR01CA223662 · NCI · UNIVERSITY OF CHICAGO · PI CHIU, BRIAN C-H, ZHANG, WEI · 2018 to 2022
$3.2M
Risk of venous thromboembolism following diagnosis and treatment of multiple myeloma: differences by raceR21HL140531 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI CALIP, GREGORY SAMPANG · 2018 to 2019
$439k
NCATS NIH HHS KL2 TR002002NCATS NIH HHS KL2TR002002NCI NIH HHS R01 CA223662NCI NIH HHS R01CA223662NHLBI NIH HHS R21 HL140531NHLBI NIH HHS R21HL140531
6 · The paper itself

Abstract

purposeTo examine the impact of pre-diagnosis depressive symptoms and mental health-related quality of life (HRQOL) on survival among older patients with multiple myeloma (MM).

methodsWe performed a retrospective cohort study using the Surveillance, Epidemiology, and End Results-Medicare Health Outcomes Survey data resource. Patients aged 65 years and older diagnosed with first primary MM between 1998 and 2014 were identified, and presence of depressive symptoms was determined based on responses to 3 depression screening questions prior to MM diagnosis. Veterans RAND 12 mental component summary (MCS) scores were analyzed to evaluate mental HRQOL. We used multivariable Cox proportional hazards models to estimate hazard ratios (HR) and 95% confidence intervals (CI) for risks of all-cause and cancer-specific mortality.

resultsOf 522 patients, mean (SD) age at diagnosis was 76.9 (6.1) years and 158 (30%) reported depressive symptoms. Patients with depressive symptoms had a higher number of comorbid conditions and nearly all (84%) scored below the median MCS. Pre-diagnosis depressive symptoms were not associated with all-cause (HR = 1.01, 95% CI 0.79-1.29) or cancer-specific mortality (HR = 0.94, 95% CI 0.69-1.28). MM patients scoring in the second MCS tertile (vs the highest tertile) had a modestly increased risk of all-cause (HR = 1.19, 95% CI 0.91-1.55) and cancer-specific mortality (HR = 1.17, 95% CI 0.86-1.60), but these estimates were not statistically significant.

conclusionPre-diagnosis depressive symptoms and lower mental HRQoL did not impact survival among older MM patients. Highly prevalent depressive symptoms among older MM patients deserve clinical attention. Such efforts can inform clinicians in tailoring care for this vulnerable population.

Indexed as

AgedAged, 80 and overCohort StudiesDepressionFemaleHumansMaleMental HealthMultiple MyelomaProspective StudiesQuality of LifeRetrospective StudiesSEER ProgramTreatment OutcomeCancer survivalDepressionElderlyMental healthMultiple myeloma

Identifiers

PMID31872292
PMCPMC7308221

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.